ClinicalTrials.gg
CompletedNCT05723770Updated Jul 4, 2025Results posted

Effects of NOV03 on the Tear Film

A Phase 4 interventional study of instillation of NOV03 in Dry Eye Disease (DED), sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc. — 1 open to participants now, 2 under way, none of them phase 3. Dry Eye Syndromes · Bausch Health Companies Inc..

Enrollment
21st of 24
33 · median 112
Started
2023
the only one that year
Phase 4
5 of 25
none open now
Registered
18th of 25
by date

Among the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 4, and was the 18th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Dry Eye Syndromes by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General/Ocular Inclusion Criteria

1. Will be at least 18 years of age at the time of consent. 2. Able to provide written voluntary . 3. Have a subject-reported history of DED in both eyes for at least 6 months prior to Visit 1. 4. Have Tear film break-up time (TFBUT) ≤5 sec at Visit

  • Have Ocular Surface Disease Index (OSDI) ≥25 at Visit 1.
  • Have an unanesthetized Schirmer's Test I ≥5 mm at Visit 1.
  • Have Meibomian Gland Dysfunction (MGD) defined as total MGD score ≥ 3 (secretion of 5 central glands on lower eyelid will be evaluated, each will be scored from 0-3; 0 = normal, 1 = thick/yellow, whitish, particulate 2 = paste; 3 = none/occluded; total score will range from 0-15) at Visit 1.
  • Have a total corneal fluorescein staining score of ≥2 and ≤11 (i.e. sum of inferior, superior, central, nasal, and temporal) according to the National Eye Institute (NEI) scale at Visit 1.
  • Have at least one eye that satisfies all criteria for 4-8 above at Visit 1.
  • Is able to fix his/her gaze for a minute, i.e. can see the fixation target and with no nystagmus
  • Is able and willing to follow instructions, including participation in all trial assessments and visits.

Exclusion criteria

Exclusion Criteria:

General/Ocular Exclusion Criteria

  1. Have any ocular surface slit-lamp findings at Visit 1 and Visit 2 and/or in the opinion of the Investigator had any findings that may have interfered with trial parameters, including

    1. history of eye trauma
    2. history of Stevens-Johnson syndrome
    3. active blepharitis or lid margin inflammation
    4. DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (as with vitamin A deficiency).
    5. abnormal lid anatomy that caused incomplete eyelid closure
    6. abnormal cornea shape (keratoconus)
    7. corneal epithelial defect or significant confluent staining or filaments
    8. history of herpetic keratitis.
    9. has a pterygium in either eye.
    10. ocular or periocular rosacea that in the judgement of the Investigator interfered with the trial
  2. Has used any topical ocular treatments, prescription dry eye therapy including varenicline nasal spray, or topical anti-glaucoma medication within 60 days prior to Visit 1.
  3. Have had a LipiFlow procedure, intense pulse light procedure or any kind of other procedure affecting meibomian glands within 6 months prior to Visit 2.
  4. Have received or removed a permanent punctum plug within 3 months (6 months for dissolvable punctum plugs) prior to Visit 2.
  5. Have used any eye drops (prescription or artificial tears) and/or TrueTearTM device (intranasal tear neurostimulator) within 24 hours before Visit 2.
  6. Have active ocular allergies or ocular allergies that are expected to be active during the trial period.
  7. Have worn contact lenses within 1 month of Visit 1 or anticipate using contact lenses during the trial.
  8. Have undergone intraocular surgery or ocular laser surgery within the previous 6 months or had any planned ocular and/or lid surgeries over the trial period.
  9. Have an active ocular or systemic infection (bacterial, viral, or fungal), including fever requiring treatment with antibiotics.
  10. Is a woman who was pregnant, nursing or planning a pregnancy.
  11. Is a woman of who is not using an acceptable means of ; acceptable methods of contraception included: hormonal (oral, implantable, injectable, or transdermal contraceptives); mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom); intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence could have been regarded as an adequate method of birth control; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.
  12. Has an uncontrolled systemic disease in the opinion of the Investigator will interfere with the trial.
  13. Has a known allergy and/or sensitivity to the drug.
  14. Has used any oral medications known to cause ocular drying (e.g., antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or is expected to be unstable during the trial.
  15. Have taken isotretinoin (e.g. Accutane, Myorisan, Claravis, Amnesteem) within 6 months of Visit 1.
  16. Has corrected VA worse than or equal to logarithm of the minimum angle of resolution (LogMAR), +0.7 as assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) charts in both eyes at Visit 1.
  17. Is currently enrolled in an investigational drug or device study or had used an investigational drug or device within 60 days of Visit 2.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Perfluorohexyloctane

    Drug: instillation of NOV03

Interventions

  • Druginstillation of NOV03

    This trial consists of 2 office visits over a period of approximately 2 weeks. At Visit 2, a designated clinical staff member or the investigator will instill 1 drop of NOV03 into each eye.

06

What researchers measure

Primary outcomes

  1. Thickness of the Mucus-aqueous Tear Film Layer

    Thickness of the mucus-aqueous layer of the tear film, measured in nanometers

    Time frame: over 4 hours following instillation of NOV03

  2. Thinning Rate of the Mucus-aqueous Tear Film Layer

    The rate of change in the thickness of the tear film mucus-aqueous layer, measured in nanometers/second

    Time frame: over 4 hours following instillation of NOV03

07

Results

Posted Jul 4, 2025
Limitations and caveats
The study had substantial technical data collection issues that prevented many of the subjects' parameter scores from being saved and analyzed. In particular for the mucus-aqueous layer thickness thinning rate (MALTR) the number of study eyes for which measurements were collected ranged from 6-11 rather than the planned 30 study eyes. Analysis was conducted without imputation of data.Thus, results were inconclusive due to data collection issues and any representation of data would be misleading.

Participant flow

Participant flow — Overall Study
MilestonePerfluorohexyloctane
Started33
Completed27
Not completed6
Withdrew: Lost to follow-up4
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryThickness of the Mucus-aqueous Tear Film Layer

Thickness of the mucus-aqueous layer of the tear film, measured in nanometers

Time frame:
over 4 hours following instillation of NOV03
Reported as:
Mean · nm
Thickness of the Mucus-aqueous Tear Film Layer
nmPerfluorohexyloctane
Thickness of the Mucus-aqueous Tear Film Layer3920.3 ± 797.7
PrimaryThinning Rate of the Mucus-aqueous Tear Film Layer

The rate of change in the thickness of the tear film mucus-aqueous layer, measured in nanometers/second

Time frame:
over 4 hours following instillation of NOV03
Reported as:
Mean · nm/s
Thinning Rate of the Mucus-aqueous Tear Film Layer
nm/sPerfluorohexyloctane
Thinning Rate of the Mucus-aqueous Tear Film Layer-62.3 ± 90.9

Adverse events

Collected over Assessed for the entire study; Visit 1 Screening through Visit 2, an average of 2 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Perfluorohexyloctane0/27 (0%)0/27 (0%)0/27 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Perfluorohexyloctane
Mean63.2 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Perfluorohexyloctane
Female2
Male25
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Perfluorohexyloctane
Hispanic or Latino9
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Perfluorohexyloctane
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American11
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Perfluorohexyloctane
United States27
08

Study locations

1 site
  • Site 101
    Miami, Florida 33125, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Dec 2023, 4 months.

Results were first posted in Jul 2025, 1 year 6 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2023
First posted
Feb 13, 2023
StartActual
Aug 14, 2023
Primary completionActual
Dec 23, 2023
CompletionActual
Dec 23, 2023
Results first posted
Jul 4, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05723770
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Aug 14, 2023
Primary completion
Dec 23, 2023
Completion
Dec 23, 2023
Results posted
Jul 4, 2025
Last update
Jul 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion